BIOMAT Database Logo BIOMAT Database Logo

Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia. 1998

N Nakamura, and T Hamazaki, and H Jokaji, and S Minami, and M Kobayashi
Department of Internal Medicine, Inami General Hospital, Higashi-Tonami-gun, Japan.

We investigated the effect of 12 months' HMG-CoA reductase inhibitor treatment on plasma polyunsaturated fatty acid concentrations in 19 patients with hyperlipidemia. Arachidonic acid concentrations were significantly increased following treatment (from 110.1 +/- 20.4 mg/l to 129.2 +/- 31.6 mg/l, P < 0.05). The ratio of eicosapentaenoic acid to arachidonic acid was significantly decreased at the end of 12 months' treatment (from 0.702 +/- 0.370 to 0.541 +/- 0.204, P < 0.05). These results suggest that HMG-CoA reductase inhibitors may increase the synthesis of metabolites from arachidonic acid in patients with hyperlipidemia, and that the addition of fish oil is more effective for the prevention of coronary heart disease than HMG-CoA reductase inhibitors alone.

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005231 Fatty Acids, Unsaturated FATTY ACIDS in which the carbon chain contains one or more double or triple carbon-carbon bonds. Fatty Acids, Polyunsaturated,Polyunsaturated Fatty Acid,Unsaturated Fatty Acid,Polyunsaturated Fatty Acids,Acid, Polyunsaturated Fatty,Acid, Unsaturated Fatty,Acids, Polyunsaturated Fatty,Acids, Unsaturated Fatty,Fatty Acid, Polyunsaturated,Fatty Acid, Unsaturated,Unsaturated Fatty Acids
D005260 Female Females
D005905 Glyburide An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide Glibenclamide,Daonil,Diabeta,Euglucon 5,Euglucon N,Glybenclamide,HB-419,HB-420,Maninil,Micronase,Neogluconin,HB 419,HB 420,HB419,HB420

Related Publications

N Nakamura, and T Hamazaki, and H Jokaji, and S Minami, and M Kobayashi
[Treatment of hyperlipidemia with HMG-CoA reductase inhibitors].
January 1989, Wiener medizinische Wochenschrift. Supplement,
N Nakamura, and T Hamazaki, and H Jokaji, and S Minami, and M Kobayashi
HMG CoA reductase inhibitors for treatment of hyperlipidemia.
May 1993, American family physician,
N Nakamura, and T Hamazaki, and H Jokaji, and S Minami, and M Kobayashi
Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors.
March 2006, Transplantation,
N Nakamura, and T Hamazaki, and H Jokaji, and S Minami, and M Kobayashi
Bile acid derived HMG-CoA reductase inhibitors.
November 1994, Biochimica et biophysica acta,
N Nakamura, and T Hamazaki, and H Jokaji, and S Minami, and M Kobayashi
Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors.
June 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
N Nakamura, and T Hamazaki, and H Jokaji, and S Minami, and M Kobayashi
HMG-CoA reductase inhibitors.
January 1985, Advances in experimental medicine and biology,
N Nakamura, and T Hamazaki, and H Jokaji, and S Minami, and M Kobayashi
HMG-CoA reductase inhibitors.
September 1990, Journal of internal medicine,
N Nakamura, and T Hamazaki, and H Jokaji, and S Minami, and M Kobayashi
HMG-CoA reductase inhibitors.
December 1993, Natural product reports,
N Nakamura, and T Hamazaki, and H Jokaji, and S Minami, and M Kobayashi
HMG CoA reductase inhibitors.
February 1994, Current opinion in lipidology,
N Nakamura, and T Hamazaki, and H Jokaji, and S Minami, and M Kobayashi
[HMG-CoA reductase inhibitors].
March 2001, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!